Molecular Templates Past Earnings Performance
Past criteria checks 0/6
Molecular Templates's earnings have been declining at an average annual rate of -12.9%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 25.4% per year.
Key information
-12.9%
Earnings growth rate
-0.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 25.4% |
Return on equity | n/a |
Net Margin | -92.8% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Molecular Templates makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 50 | -47 | 23 | 0 |
31 Mar 23 | 48 | -60 | 24 | 0 |
31 Dec 22 | 20 | -93 | 26 | 0 |
30 Sep 22 | 35 | -81 | 27 | 0 |
30 Jun 22 | 33 | -87 | 31 | 0 |
31 Mar 22 | 44 | -78 | 33 | 0 |
31 Dec 21 | 39 | -83 | 34 | 0 |
30 Sep 21 | 24 | -101 | 33 | 0 |
30 Jun 21 | 26 | -94 | 32 | 0 |
31 Mar 21 | 18 | -110 | 29 | 0 |
31 Dec 20 | 19 | -105 | 27 | 0 |
30 Sep 20 | 22 | -92 | 26 | 0 |
30 Jun 20 | 21 | -107 | 23 | 0 |
31 Mar 20 | 19 | -85 | 21 | 0 |
31 Dec 19 | 22 | -69 | 20 | 0 |
30 Sep 19 | 21 | -60 | 18 | 0 |
30 Jun 19 | 24 | -27 | 17 | 0 |
31 Mar 19 | 20 | -28 | 16 | 0 |
31 Dec 18 | 13 | -30 | 14 | 0 |
30 Sep 18 | 9 | -31 | 14 | 0 |
30 Jun 18 | 3 | -36 | 12 | 0 |
31 Mar 18 | 2 | -31 | 11 | 0 |
31 Dec 17 | 3 | -24 | 10 | 0 |
30 Sep 17 | 3 | -20 | 8 | 0 |
30 Jun 17 | 2 | -13 | 6 | 0 |
31 Mar 17 | 3 | -11 | 5 | 0 |
31 Dec 16 | 2 | -13 | 4 | 0 |
31 Dec 15 | 1 | -7 | 3 | 0 |
Quality Earnings: NZW is currently unprofitable.
Growing Profit Margin: NZW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NZW is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare NZW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NZW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: NZW's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.